info@biomedres.us   +1 (720) 414-3554   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Review ArticleOpen Access

The Human Equilibrative Nucleoside Transporter Protein1 (Hent1) is a Predict /Prognostic Factor in Resected Pancreatic Cancer Patients

Volume 9 - Issue 5

Zhao Hongbing1, Zhang Xifeng2, Wang Jingjing1 and Li Xiao Rui*1

  • Author Information Open or Close
    • 1Department of Oncology, First Affiliated Hospital of Xinxiang Medical College, China
    • 2 ShangQiu Medical School, Shang Qiu, China

    *Corresponding author: Li Xiao Rui, Department of Oncology, First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan, China

Received: October 03, 2018;   Published: October 10, 2018

DOI: 10.26717/BJSTR.2018.09.001860

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Pancreatic cancer is currently one of the deadliest of the solid malignancies and has a particularly low survival rate in the future because targeted therapies for other cancers are becoming more advanced than those for pancreatic cancer [1]. The optimal treatment first and foremost depends on careful accurate staging. The American Joint Committee on Cancer (AJCC) staging system, which includes the TNM classification, is the most widely used system to stage pancreatic cancer [2]. Patients with Stage I/II disease should undergo surgical resection followed by adjuvant therapy, while patients with Stage III borderline resectable cancers should undergo neoadjuvant therapy prior to resection. Patients with stage III locally advanced disease should be treated with chemotherapy and/or chemoradiotherapy. Patients with Stage IV and good performance status may receive systemic therapy and those with poor overall health should be given supportive therapy [3].

Abstract | Introduction| Conclusion| References|